vTv Therapeutics (VTVT) reported Thursday screening has been reinitiated in its phase 3 trial of cadisegliatin as an adjunctive treatment of type 1 diabetes following a protocol amendment.
Continuous glucose monitors will now be provided to participants to inform the primary study endpoint, which is the number of level 2 and level 3 hypoglycemic events, the company said.
The amendment shortens trial duration to six months from 12, expediting time to topline data, the company said.
"We look forward to reporting topline Phase 3 data from CATT1 in the second half of 2026," said CEO Paul Sekhri.
The shares were up over 3% in recent trading.
Price: 21.96, Change: +0.65, Percent Change: +3.06
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。